Whitehawk Therapeutics is a clinical-stage biotechnology enterprise focused on discovering, developing, and commercializing next-generation antibody-drug conjugates designed to overcome limitations associated with conventional targeted cancer therapies. The company engineers precision oncology assets tailored to attack difficult-to-treat solid tumors, including lung and gynecological malignancies, by targeting clinically validated proteins overexpressed on cancer cells while sparing healthy normal tissues.